Outcomes in Progressive Large B-Cell Lymphomas Following CD19-Specific CAR T Cells

Warren Fingrut, MD, discussed a study looking at HLA antibody burden among patients with blood cancers, particularly women who have carried multiple pregnancies.

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

Natasha Leighl, MD, MMSc, BSc, discussed the analysis of the CHRYSALIS study that was presented at the 2024 American Association for Cancer Research Annual Meeting.

Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.